instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
What is the median rate of Progression-Free Survival in patients who have been treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Can you inform me about the median PFS rate in patients that were treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What is the median PFS rate for patients that have undergone Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What is the median PFS rate for patients that have undergone Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Could you tell me the median Progression-Free Survival rate for patients who received Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
What’s the median rate of PFS in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: What’s the median rate of PFS in patients treated with Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Can you share the median Progression-Free Survival rate in patients who have received Idecabtagene Vicleucel (Ide-Cel) regimen? | Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Idecabtagene Vicleucel (Ide-Cel) regimen?
### Response: Patients treated with the Idecabtagene Vicleucel (Ide-Cel) have a median Progression-Free Survival (PFS) rate of 13.3 months, with a 95% CI of (11.8, 16.1). |
Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Can you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What’s the median PFS associated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Could you provide the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: I’d like to know the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Do you have information on the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Can you inform me about the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd). | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: I’m interested in the median PFS of Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd).
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Could you tell me the median PFS for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median PFS rate for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median PFS rate for Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd)?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median PFS rate in patients who have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What’s the median PFS rate for patients receiving Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What is the median PFS rate for patients that have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
What’s the median rate of PFS in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen? | Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) regimen?
### Response: Patients treated with the Daratumumab+Pomalidomide+Dexamethasone (DPd) ;
Daratumumab+Bortezomib+Dexamethasone (DVd) ;
Ixazomib+Lenalidomide+Dexamethasone (IRd) ;
Carfilzomib+Dexamethasone (Kd) ;
Elotuzumab+Pomalidomide+Dexamethasone (EPd) have a median Progression-Free Survival (PFS) rate of 4.4 months, with a 95% CI of (3.4, 5.9). |
Subsets and Splits